Why Is DAVITA INC (DVA) Stock Down Today?

DaVita Inc. (DVA) shares fell 6.23% to close at $175.35. The primary driver for the decline was news that the Trump administration is proposing a Kidney Care National Plan aimed at boosting competition in the dialysis market.

What Happened

The stock dropped alongside Fresenius Medical Care (FMS) as reports indicated Health and Human Services Secretary RFK Jr. is planning reforms to the dialysis sector. The proposed plan seeks to increase competition within the kidney care industry. DaVita also announced it has scheduled its third quarter 2026 investor conference call. The company’s stock had previously traded in a wide range, with a 52-week high of $247.49 and a low of $101.00.

What The Data Shows

Intraday trading revealed significant volatility. The stock opened at $189.31, a 1.2% gap up from the prior close of $187.00. It reached a session high of $191.20 at 10:50 AM ET before sliding to a session low of $171.09 at 2:40 PM ET. Volume reached 1.5 million shares, which is 2.0 times the three-month daily average. Fundamentals show a market cap of $11.9 billion, a P/E ratio of 15.9, and revenue growth of 6.4% over the trailing twelve months. The net margin stands at 6.0%, and the beta is 0.80. Recent insider activity includes one sale totaling $36.5 million, with the most recent filing on August 4, 2026. Berkshire Hathaway Inc. sold shares on July 31, 2026. Congressional disclosures show one buy and one sell, with the most recent filing on August 5, 2026.

What To Watch

Investors will monitor the company’s scheduled earnings release for October 29. The market will also assess how the proposed kidney care plan impacts future revenue projections and competitive dynamics within the dialysis sector.